Silodosin
💊 Brand Formulations & Prices
20 brands sorted by unit price
Silofit
Siloflo
Silofast
Flowrap
Prostanor
Rapasin
Rapiflo
Rapilief
Relsin
Silosin
Silofit
Siloflo
Silofast
Flowrap
Prostanor
Rapilief
Relsin
Silosin
Rapasin
Rapiflo
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesFlowrap capsule is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
Highly effective for the treatment of Benign Prostatic Hyperplasia.
Highest uroselectivity to alpha-1 adrenergic receptor.
Effective treatment option for BPH who are not responding to Tamsulosin.
Dose not cause orthostatic hypotension.
Convenient once-daily dosing.
Flowrap is not indicated for the treatment of hypertension.
The recommended dose is Silodosin 8 mg orally once daily with a meal. 4 mg capsules taken orally once daily with a meal for those with moderate renal impairment (CrCl 30-50 mL/min).
Patients with severe renal & hepatic impairment, concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) and patients with a history of hypersensitivity to Silodosin.
Most common adverse reactions are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis and nasal congestion.
Postural hypotension with or without symptoms (e.g. dizziness) may develop when beginning Flowrap treatment. Flowrap should not be used in combination with other alpha-blocker. Inform patients planning cataract surgery to notify their ophthalmologist that they are taking Flowrap because of the possibility of Intraoperative Floppy Iris Syndrome (IFIS)
Silodosin is a selective antagonist of post-synaptic alpha-1 adrenoreceptors, which are located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra. Blockade of these alpha-1 adrenoreceptors can cause smooth muscle in these tissues to relax, resulting in an improvement in urine flow and a reduction in BPH symptoms.